AbbVie, Samsung Bioepis in Deal; Humira Biosimilar U.S. Release in 2023 AbbVie, Samsung Bioepis in Deal; Humira Biosimilar U.S. Release in 2023

AbbVie Inc on Thursday said it signed a deal with Samsung Bioepis and its joint venture partner Biogen Inc that would fend off U.S. competition of their biosimilar version to blockbuster drug Humira until 2023.Reuters Health Information

Source: Medscape Medical News Headlines - April 6, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news